| KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD | American Journal of Kidney Diseases | 2014 | 866 |
| Pre-eclampsia part 1: current understanding of its pathophysiology | Nature Reviews Nephrology | 2014 | 585 |
| Long-term risks for kidney donors | Kidney International | 2014 | 482 |
| Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control | Kidney International | 2014 | 447 |
| The gut microbiome, kidney disease, and targeted interventions | Journal of the American Society of Nephrology: JASN | 2014 | 406 |
| Patency rates of the arteriovenous fistula for hemodialysis: a systematic review and meta-analysis | American Journal of Kidney Diseases | 2014 | 388 |
| Acute kidney injury-epidemiology, outcomes and economics | Nature Reviews Nephrology | 2014 | 386 |
| The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review | Journal of the American Society of Nephrology: JASN | 2014 | 385 |
| Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward | Kidney International | 2014 | 375 |
| Inflammatory processes in renal fibrosis | Nature Reviews Nephrology | 2014 | 375 |
| Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD | American Journal of Nephrology | 2014 | 331 |
| Diabetic kidney disease: a report from an ADA Consensus Conference | American Journal of Kidney Diseases | 2014 | 324 |
| Mechanisms of muscle wasting in chronic kidney disease | Nature Reviews Nephrology | 2014 | 312 |
| Fibroblast growth factor-23 and cardiovascular events in CKD | Journal of the American Society of Nephrology: JASN | 2014 | 306 |
| Exercise training in adults with CKD: a systematic review and meta-analysis | American Journal of Kidney Diseases | 2014 | 305 |
| GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration | American Journal of Kidney Diseases | 2014 | 300 |
| US Renal Data System 2013 Annual Data Report | American Journal of Kidney Diseases | 2014 | 299 |
| Regulated cell death in AKI | Journal of the American Society of Nephrology: JASN | 2014 | 291 |
| SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice | American Journal of Physiology - Renal Physiology | 2014 | 290 |
| Diabetic nephropathy - complications and treatment | International Journal of Nephrology and Renovascular Disease | 2014 | 286 |
| KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient | Kidney International | 2014 | 285 |
| GFR estimation: from physiology to public health | American Journal of Kidney Diseases | 2014 | 283 |
| Measuring GFR: a systematic review | American Journal of Kidney Diseases | 2014 | 274 |
| Clinical practice guideline on diagnosis and treatment of hyponatraemia | Nephrology Dialysis Transplantation | 2014 | 271 |
| Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments | Kidney International | 2014 | 262 |
